Current State of Platinum Complexes for the Treatment of Advanced and Drug-Resistant Breast Cancers

Biersack, Bernhard; Schobert, Rainer

doi:10.1007/978-3-030-20301-6_13

Cited by 6 publications

(5 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a vast repertoire of chemotherapeutic agents is available, e.g., 5-fluorouracil (5-FU), cyclophosphamide, carboplatin, taxanes such as paclitaxel and docetaxel, anthracyclines such as doxorubicin [31][32][33]. Chemotherapeutics correspond to the principal remedies for women whose cancer has become metastatic, but also when it is diagnosed or next to early interventions.…”

Section: Outline On the Therapeutic Approaches For Bc Treatmentmentioning

confidence: 99%

“…In particular, for invasive disease such as TNBC as well as for other metastatic BCs, wide-spectrum and effective chemotherapy agents are still required. Currently, this clinical area is covered only by platinum(II) coordination complexes, including the worldwide approved Cisplatin ( c DDP), Oxaliplatin and Carboplatin, together with the restricted Nedaplatin and Lobaplatin [ 33 , 82 ]. Of course, absence of any biological selectivity leads to severe off-targets effects especially on high proliferating tissues.…”

Section: An Outlook On Ru-based Complexes In the Landscape Of Antimentioning

confidence: 99%

“…Using these models, cationic Ru/DOTAP nanoformulations have always emerged as the most effective in reducing the proliferation of BCC. In this context, given that cisplatin ( c DDP) is used in guideline treatment protocols for various BCs, and that these BCC are sensitive to cisplatin in vitro , we used c DDP as cytotoxic reference drug [ 33 , 82 ]. Results standardization in favor of the ruthenium aliquot included in DOTAP nanosystems reveals IC 50 values of about 3÷4 μM in CG-5 cells, and of about 10 μM in MCF-7 cells, indicative of a remarkable antiproliferative bioactivity.…”

Section: Selectivity and Efficacy Of Nucleolipid Ru-based Nanoformmentioning

confidence: 99%

See 2 more Smart Citations

Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems

Ferraro

Piccolo

Misso

et al. 2020

Cells

View full text Add to dashboard Cite

In this review we have showcased the preclinical development of original amphiphilic nanomaterials designed for ruthenium-based anticancer treatments, to be placed within the current metallodrugs approach leading over the past decade to advanced multitarget agents endowed with limited toxicity and resistance. This strategy could allow for new options for breast cancer (BC) interventions, including the triple-negative subtype (TNBC) with poor therapeutic alternatives. BC is currently the second most widespread cancer and the primary cause of cancer death in women. Hence, the availability of novel chemotherapeutic weapons is a basic requirement to fight BC subtypes. Anticancer drugs based on ruthenium are among the most explored and advanced next-generation metallotherapeutics, with NAMI-A and KP1019 as two iconic ruthenium complexes having undergone clinical trials. In addition, many nanomaterial Ru complexes have been recently conceived and developed into anticancer drugs demonstrating attractive properties. In this field, we focused on the evaluation of a Ru(III) complex—named AziRu—incorporated into a suite of both zwitterionic and cationic nucleolipid nanosystems, which proved to be very effective for the in vivo targeting of breast cancer cells (BBC). Mechanisms of action have been widely explored in the context of preclinical evaluations in vitro, highlighting a multitarget action on cell death pathways which are typically deregulated in neoplasms onset and progression. Moreover, being AziRu inspired by the well-known NAMI-A complex, information on non-nanostructured Ru-based anticancer agents have been included in a precise manner.

show abstract

Section: Outline On the Therapeutic Approaches For Bc Treatmentmentioning

confidence: 99%

Section: An Outlook On Ru-based Complexes In the Landscape Of Antimentioning

confidence: 99%

Section: Selectivity and Efficacy Of Nucleolipid Ru-based Nanoformmentioning

confidence: 99%

See 1 more Smart Citation

Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems

Ferraro

Piccolo

Misso

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…Triple-negative breast cancer (TNBC) is the most dangerous subtype with the worst therapeutic prognosis and outcomes due to the absence of receptors for estrogen, progesterone, and HER2. Chemotherapy is the standard treatment for TNBC, and cisplatin is widely used in the clinical management of TNBC [ 1 – 3 ]. Therefore, the loss of sensitivity to chemotherapy is the primary cause of therapeutic failure.…”

Section: Introductionmentioning

confidence: 99%

MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3–phospho-BAD pathway

et al. 2022

View full text Add to dashboard Cite

Breast cancer is one of the leading causes of mortality among women. Triple-negative breast cancer (TNBC) is responsible for a large percentage of all breast cancer deaths in women. This study demonstrated the function of Myb-like, SWIRM, and MPN domains 1 (MYSM1), an H2A deubiquitinase (DUB), in TNBC. MYSM1 expression was drastically decreased in breast cancer, especially in TNBC, suggesting a potential anticancer effect. Overexpressing and suppressing MYSM1 expression in TNBC cell lines led to significant biological changes in cell proliferation. Furthermore, MYSM1 overexpression increased cisplatin-induced apoptosis, which might be attributed to RSK3 inactivation and the subsequently decreased phosphorylation of Bcl-2 antagonist of cell death (BAD) (Ser 112). The findings suggest that MYSM1 is a potential target for regulating cell apoptosis and suppressing resistance to cisplatin in TNBC.

show abstract

“…Metal ions complexes of the first transition series have been also proposed as cytotoxic and/or cytostatic agents in many tumors [35,36] but at the present they results less effective as drugs compared to those formed by heavier transition metal as platinum or gold [37][38][39].…”

Section: Introductionmentioning

confidence: 99%

The Effects on Angiogenesis of Relevant Inorganic Chemotherapeutics

Marzo

Mendola

2021

CTMC

View full text Add to dashboard Cite

: Angiogenesis is a key process allowing the formation of blood vessels. It is crucial for all the tissue and organs, ensuring their function and growth. Angiogenesis is finely controlled by several mechanisms involving complex interactions between pro- or antiangiogenic factors and an imbalance in this control chain may result in pathological conditions. Metals as copper, zinc and iron cover an essential role in regulating angiogenesis, thus therapies having physiological metals as target have been proposed. Also, some complexes of heavier metal ions (e.g Pt, Au, Ru) are currently used as established or experimental anticancer agents targeting genomic or non-genomic targets. These molecules may affect the angiogenic mechanisms determining different effects that have been only poorly and non-systematically investigated so far. Accordingly, in this review article we aim to recapitulate the impact on the angiogenic process of some reference anticancer drugs, and how it is connected to the overall pharmacological effects. Also, we highlight how the activity of these drugs can be related to the role of biological essential metal ions. Overall, this may allow a deeper description and understanding of the antineoplastic activity of both approved or experimental metal complexes, providing important insights for the synthesis of new inorganic drugs able to overcome resistance and recurrence phenomena.

show abstract

Current State of Platinum Complexes for the Treatment of Advanced and Drug-Resistant Breast Cancers

Cited by 6 publications

References 73 publications

Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems

Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems

MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3–phospho-BAD pathway

The Effects on Angiogenesis of Relevant Inorganic Chemotherapeutics

Contact Info

Product

Resources

About